Cargando…

A role for eukaryotic initiation factor 4B overexpression in the pathogenesis of diffuse large B-cell lymphoma

Dysregulated expression of factors that control protein synthesis is associated with poor prognosis of many cancers, but the underlying mechanisms are not well defined. Analysis of the diffuse large B-cell lymphoma (DLBCL) translatome revealed selective upregulation of mRNAs encoding anti-apoptotic...

Descripción completa

Detalles Bibliográficos
Autores principales: Horvilleur, E, Sbarrato, T, Hill, K, Spriggs, R V, Screen, M, Goodrem, P J, Sawicka, K, Chaplin, L C, Touriol, C, Packham, G, Potter, K N, Dirnhofer, S, Tzankov, A, Dyer, M J S, Bushell, M, MacFarlane, M, Willis, A E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017261/
https://www.ncbi.nlm.nih.gov/pubmed/24135829
http://dx.doi.org/10.1038/leu.2013.295
_version_ 1782479938588246016
author Horvilleur, E
Sbarrato, T
Hill, K
Spriggs, R V
Screen, M
Goodrem, P J
Sawicka, K
Chaplin, L C
Touriol, C
Packham, G
Potter, K N
Dirnhofer, S
Tzankov, A
Dyer, M J S
Bushell, M
MacFarlane, M
Willis, A E
author_facet Horvilleur, E
Sbarrato, T
Hill, K
Spriggs, R V
Screen, M
Goodrem, P J
Sawicka, K
Chaplin, L C
Touriol, C
Packham, G
Potter, K N
Dirnhofer, S
Tzankov, A
Dyer, M J S
Bushell, M
MacFarlane, M
Willis, A E
author_sort Horvilleur, E
collection PubMed
description Dysregulated expression of factors that control protein synthesis is associated with poor prognosis of many cancers, but the underlying mechanisms are not well defined. Analysis of the diffuse large B-cell lymphoma (DLBCL) translatome revealed selective upregulation of mRNAs encoding anti-apoptotic and DNA repair proteins. We show that enhanced synthesis of these proteins in DLBCL is mediated by the relief of repression that is normally imposed by structure in the 5′-untranslated regions of their corresponding mRNAs. This process is driven by signaling through mammalian target of rapamycin, resulting in increased synthesis of eukaryotic initiation factor (eIF) 4B complex (eIF4B), a known activator of the RNA helicase eIF4A. Reducing eIF4B expression alone is sufficient to decrease synthesis of proteins associated with enhanced tumor cell survival, namely DAXX, BCL2 and ERCC5. Importantly, eIF4B-driven expression of these key survival proteins is directly correlated with patient outcome, and eIF4B, DAXX and ERCC5 are identified as novel prognostic markers for poor survival in DLBCL. Our work provides new insights into the mechanisms by which the cancer-promoting translational machinery drives lymphomagenesis.
format Online
Article
Text
id pubmed-4017261
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-40172612014-05-13 A role for eukaryotic initiation factor 4B overexpression in the pathogenesis of diffuse large B-cell lymphoma Horvilleur, E Sbarrato, T Hill, K Spriggs, R V Screen, M Goodrem, P J Sawicka, K Chaplin, L C Touriol, C Packham, G Potter, K N Dirnhofer, S Tzankov, A Dyer, M J S Bushell, M MacFarlane, M Willis, A E Leukemia Original Article Dysregulated expression of factors that control protein synthesis is associated with poor prognosis of many cancers, but the underlying mechanisms are not well defined. Analysis of the diffuse large B-cell lymphoma (DLBCL) translatome revealed selective upregulation of mRNAs encoding anti-apoptotic and DNA repair proteins. We show that enhanced synthesis of these proteins in DLBCL is mediated by the relief of repression that is normally imposed by structure in the 5′-untranslated regions of their corresponding mRNAs. This process is driven by signaling through mammalian target of rapamycin, resulting in increased synthesis of eukaryotic initiation factor (eIF) 4B complex (eIF4B), a known activator of the RNA helicase eIF4A. Reducing eIF4B expression alone is sufficient to decrease synthesis of proteins associated with enhanced tumor cell survival, namely DAXX, BCL2 and ERCC5. Importantly, eIF4B-driven expression of these key survival proteins is directly correlated with patient outcome, and eIF4B, DAXX and ERCC5 are identified as novel prognostic markers for poor survival in DLBCL. Our work provides new insights into the mechanisms by which the cancer-promoting translational machinery drives lymphomagenesis. Nature Publishing Group 2014-05 2013-11-01 /pmc/articles/PMC4017261/ /pubmed/24135829 http://dx.doi.org/10.1038/leu.2013.295 Text en Copyright © 2014 Macmillan Publishers Limited http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
spellingShingle Original Article
Horvilleur, E
Sbarrato, T
Hill, K
Spriggs, R V
Screen, M
Goodrem, P J
Sawicka, K
Chaplin, L C
Touriol, C
Packham, G
Potter, K N
Dirnhofer, S
Tzankov, A
Dyer, M J S
Bushell, M
MacFarlane, M
Willis, A E
A role for eukaryotic initiation factor 4B overexpression in the pathogenesis of diffuse large B-cell lymphoma
title A role for eukaryotic initiation factor 4B overexpression in the pathogenesis of diffuse large B-cell lymphoma
title_full A role for eukaryotic initiation factor 4B overexpression in the pathogenesis of diffuse large B-cell lymphoma
title_fullStr A role for eukaryotic initiation factor 4B overexpression in the pathogenesis of diffuse large B-cell lymphoma
title_full_unstemmed A role for eukaryotic initiation factor 4B overexpression in the pathogenesis of diffuse large B-cell lymphoma
title_short A role for eukaryotic initiation factor 4B overexpression in the pathogenesis of diffuse large B-cell lymphoma
title_sort role for eukaryotic initiation factor 4b overexpression in the pathogenesis of diffuse large b-cell lymphoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017261/
https://www.ncbi.nlm.nih.gov/pubmed/24135829
http://dx.doi.org/10.1038/leu.2013.295
work_keys_str_mv AT horvilleure aroleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma
AT sbarratot aroleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma
AT hillk aroleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma
AT spriggsrv aroleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma
AT screenm aroleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma
AT goodrempj aroleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma
AT sawickak aroleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma
AT chaplinlc aroleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma
AT touriolc aroleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma
AT packhamg aroleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma
AT potterkn aroleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma
AT dirnhofers aroleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma
AT tzankova aroleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma
AT dyermjs aroleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma
AT bushellm aroleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma
AT macfarlanem aroleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma
AT willisae aroleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma
AT horvilleure roleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma
AT sbarratot roleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma
AT hillk roleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma
AT spriggsrv roleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma
AT screenm roleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma
AT goodrempj roleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma
AT sawickak roleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma
AT chaplinlc roleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma
AT touriolc roleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma
AT packhamg roleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma
AT potterkn roleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma
AT dirnhofers roleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma
AT tzankova roleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma
AT dyermjs roleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma
AT bushellm roleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma
AT macfarlanem roleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma
AT willisae roleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma